JP2009538415A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009538415A5 JP2009538415A5 JP2009506735A JP2009506735A JP2009538415A5 JP 2009538415 A5 JP2009538415 A5 JP 2009538415A5 JP 2009506735 A JP2009506735 A JP 2009506735A JP 2009506735 A JP2009506735 A JP 2009506735A JP 2009538415 A5 JP2009538415 A5 JP 2009538415A5
- Authority
- JP
- Japan
- Prior art keywords
- steroid receptor
- receptor
- cancer
- immunoassay
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 46
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 39
- 108010085012 Steroid Receptors Proteins 0.000 claims description 34
- 102000005969 steroid hormone receptors Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 31
- 238000003018 immunoassay Methods 0.000 claims description 22
- 239000008280 blood Substances 0.000 claims description 17
- 210000004369 blood Anatomy 0.000 claims description 17
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 238000001514 detection method Methods 0.000 claims description 5
- 229940126588 endocrine therapeutic agent Drugs 0.000 claims description 5
- 102100032187 Androgen receptor Human genes 0.000 claims description 4
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 4
- 108010007005 Estrogen Receptor alpha Proteins 0.000 claims description 4
- 102100038595 Estrogen receptor Human genes 0.000 claims description 4
- 102100025803 Progesterone receptor Human genes 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 108010080146 androgen receptors Proteins 0.000 claims description 4
- 239000003886 aromatase inhibitor Substances 0.000 claims description 4
- 108090000468 progesterone receptors Proteins 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009261 endocrine therapy Methods 0.000 claims description 3
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 claims description 3
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 claims description 2
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims description 2
- 108010041356 Estrogen Receptor beta Proteins 0.000 claims description 2
- 102100029951 Estrogen receptor beta Human genes 0.000 claims description 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 2
- 229960002932 anastrozole Drugs 0.000 claims description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 229960000255 exemestane Drugs 0.000 claims description 2
- 229950011548 fadrozole Drugs 0.000 claims description 2
- 238000002875 fluorescence polarization Methods 0.000 claims description 2
- 229960002258 fulvestrant Drugs 0.000 claims description 2
- 229960003881 letrozole Drugs 0.000 claims description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
- 210000004897 n-terminal region Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 4
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74501206P | 2006-04-18 | 2006-04-18 | |
| US60/745,012 | 2006-04-18 | ||
| PCT/US2007/066849 WO2007121459A2 (en) | 2006-04-18 | 2007-04-18 | Detection of steroid receptors on circulating carcinoma cells and treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009538415A JP2009538415A (ja) | 2009-11-05 |
| JP2009538415A5 true JP2009538415A5 (https=) | 2011-04-28 |
| JP5078100B2 JP5078100B2 (ja) | 2012-11-21 |
Family
ID=38610453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009506735A Expired - Fee Related JP5078100B2 (ja) | 2006-04-18 | 2007-04-18 | 循環癌細胞におけるステロイド受容体の検出および処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090291920A1 (https=) |
| EP (1) | EP2008107A4 (https=) |
| JP (1) | JP5078100B2 (https=) |
| CA (1) | CA2647743A1 (https=) |
| MX (1) | MX2008013331A (https=) |
| WO (1) | WO2007121459A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2582713A1 (en) * | 2004-10-06 | 2006-04-20 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment |
| CA2684265A1 (en) * | 2007-04-19 | 2008-10-30 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment |
| US20110144198A1 (en) | 2008-05-16 | 2011-06-16 | Atlas Antibodies Ab | Breast cancer prognostics |
| EP2591363B1 (en) * | 2010-07-07 | 2017-09-20 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| TWI577389B (zh) * | 2010-10-14 | 2017-04-11 | 維里德克斯有限責任公司 | 使用多專一性捕捉及雞尾酒檢測試劑檢測胰臟病患之循環腫瘤細胞的方法及套組 |
| US20120252038A1 (en) * | 2011-04-01 | 2012-10-04 | Chianese David A | Steroid receptor assays |
| US10175240B2 (en) | 2012-08-23 | 2019-01-08 | The Regents Of The University Of Colorado, A Body Corporate | Method for determining breast cancer treatment |
| US20150233932A1 (en) * | 2013-02-19 | 2015-08-20 | Ching-Ping Tseng | Methods, Systems, and Compositions for Enrichment of Rare Cells |
| IT201800004137A1 (it) * | 2018-03-30 | 2019-09-30 | Domenico Marina Di | Metodo di screening in vitro per diagnosi precoce dei tumori del cavo orale e relativo kit, basato in particolare su saggio elisa |
| EP3906412A1 (en) * | 2019-01-03 | 2021-11-10 | Meso Scale Technologies, LLC | Compositions and methods for carrying out assay measurements |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020172987A1 (en) * | 1998-02-12 | 2002-11-21 | Terstappen Leon W.M.M. | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| BR0207290A (pt) * | 2001-02-16 | 2005-06-07 | Immunivest Corp | Método para analisar um paciente quanto à presença de uma malignidade, célula maligna isolada das células cultivadas, vacina de tumor, molécula associada com diátese de tumor alterada, métodos para determinar alterações em moléculas associadas com diátese de tumor como um meio para predizer a eficácia da terapia, como um meio para analisar dosagem apropriada para terapia, como um meio para monitorar eficácia da terapia, como um meio para analisar progressão de câncer, para realizar uma biópsia de corpo inteiro em um paciente, e para identificar alterações em uma célula de tumor circulante relativamente a células presentes numa massa de tumor in situ, e, kit de teste para analisar uma amostra de paciente quanto à presença de uma célula maligna não-hematopoiética |
| EP1597353B1 (en) * | 2003-02-27 | 2010-11-24 | Veridex, LLC | CIRCULATING TUMOR CELLS (CTC's): EARLY ASSESSMENT OF TIME TO PROGRESSION SURVIVAL AND RESPONSE TO THERAPY IN METASTATIC CANCER PATIENTS |
| JP2006525030A (ja) * | 2003-05-07 | 2006-11-09 | セダーズ−シナイ メディカル センター | 細胞内エストラジオール結合タンパク質、このタンパク質をコードするポリヌクレオチドおよびこのタンパク質を過剰発現する細胞 |
| CA2582713A1 (en) * | 2004-10-06 | 2006-04-20 | Wellstat Biologics Corporation | Detection of elevated levels of her-2/neu protein on circulating cancer cells and treatment |
| GB0512429D0 (en) * | 2005-06-17 | 2005-07-27 | Smithkline Beecham Corp | Novel compound |
| US20100105145A1 (en) * | 2005-07-01 | 2010-04-29 | Dako Denmark A/S | Method of simultaneously visualizing multiple biological targets |
| EP1816477A1 (en) * | 2006-02-06 | 2007-08-08 | F. Hoffmann-la Roche AG | The use of natriuretic peptides and placenta growth factor levels for risk stratification of individuals elected for cardiac stress testing |
-
2007
- 2007-04-18 MX MX2008013331A patent/MX2008013331A/es active IP Right Grant
- 2007-04-18 CA CA002647743A patent/CA2647743A1/en not_active Abandoned
- 2007-04-18 WO PCT/US2007/066849 patent/WO2007121459A2/en not_active Ceased
- 2007-04-18 EP EP07760823A patent/EP2008107A4/en not_active Withdrawn
- 2007-04-18 US US12/296,458 patent/US20090291920A1/en not_active Abandoned
- 2007-04-18 JP JP2009506735A patent/JP5078100B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009538415A5 (https=) | ||
| Rugo et al. | Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer | |
| Salminen et al. | Associations between serum testosterone fall and cognitive function in prostate cancer patients | |
| Aranda et al. | Effects of sex steroids on cardiovascular risk profile in transgender men under gender affirming hormone therapy | |
| Zhou et al. | Intermittent hypoxia-induced cardiomyopathy and its prevention by Nrf2 and metallothionein | |
| Salminen et al. | Estradiol and cognition during androgen deprivation in men with prostate carcinoma | |
| Ingle et al. | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole | |
| JP2009525478A5 (https=) | ||
| Yang et al. | NU7441 enhances the radiosensitivity of liver cancer cells | |
| Zahran et al. | Increased frequency and FOXP3 expression of human CD8+ CD25High+ T lymphocytes and its relation to CD4 regulatory T cells in patients with hepatocellular carcinoma | |
| Vatsalya et al. | A review on the sex differences in organ and system pathology with alcohol drinking | |
| ATE497165T1 (de) | Erkennung eines erhöhten spiegels von her-2/neu- proteinen in zirkulierenden krebszellen und dessen behandlung | |
| de la Torre et al. | A phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect | |
| RU2012148816A (ru) | Метод диагностики для определения клеток ex vivo | |
| Feldt-Rasmussen et al. | Thyroglobulin autoantibodies as surrogate biomarkers in the management of patients with differentiated thyroid carcinoma | |
| Sakata et al. | Sex-different effect of angiotensin II type 2 receptor on ischemic brain injury and cognitive function | |
| Ma et al. | Indoleamine-2, 3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer | |
| Miyao et al. | YM155 reverses Cabazitaxel resistance in Castration-resistant prostate cancer by reducing survivin expression | |
| JP2015508903A5 (https=) | ||
| Hsu et al. | Combined CRAFITY score and α-fetoprotein response predicts treatment outcomes in patients with unresectable hepatocellular carcinoma receiving anti-programmed death-1 blockade-based immunotherapy | |
| Sprenger et al. | Androgen receptor splice variant V7 (AR-V7) in circulating tumor cells: a coming of age for AR splice variants? | |
| Lan et al. | Effect of radiation fractionation on IDO1 via the NF-κB/COX2 axis in non-small cell lung cancer | |
| Khan et al. | Depression enhanced the production of autoantibodies against 16α‑hydroxyestrone-estrogen receptor adduct in breast cancer | |
| Luo et al. | Senolytic drugs dasatinib and quercetin promote skin papilloma progression by eliminating senescent cells and impairing immune surveillance | |
| JP2019515035A5 (https=) |